Dare Bioscience, Inc.: Lind Global Fund III LP amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Lind Global Fund III LP amended its Schedule 13G filing on Dare Bioscience, Inc., disclosing a change in its passive stake in the company. The filing, submitted to the SEC under accession number 0000929638-26-004365, updates the fund's previously reported ownership position. The amendment signals a shift in Lind Global's holdings in the clinical-stage women's health company, though the filing did not specify the exact size or direction of the change. Investors will watch for further 13G or 13D filings to gauge whether the fund intends to remain a passive holder or take a more active role.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Lind Global Fund III LP, Dare Bioscience, Inc.